ECONOMYNEXT — Sri Lanka’s cabinet of ministers has approved a 225,000 dollar contract to procure 6,000 pre-filled syringes of Adalimumab, a drug used to treat chronic and autoimmune diseases, from India’s Reliance Life Sciences Pvt Ltd.
The decision follows an international competitive bidding process where four bidders submitted proposals for the 40mg (0.8ml) syringes.
Cabinet Spokesman and Minister of Health Nalinda Jayatissa told reporters that the contract was awarded to Reliance Life Sciences as the lowest responsive bidder, following recommendations from the High-Level Standing Procurement Committee.
Addressing concerns regarding the quality of imported medicines, Jayatissa noted that nearly 85 percent of Sri Lanka’s pharmaceutical supplies are currently sourced from India.
“Regardless of whether they come from India, Pakistan, Bangladesh, or Europe, all medicines must undergo the regulatory process within the National Medicines Regulatory Authority (NMRA),” Jayatissa said.
The Minister emphasized that the government is maintaining a rigorous inspection regime for high-risk medications.
“We have several categories of drugs that we focus on with extra attention. Those that could put lives at risk are constantly being tested and inspected. Registration for those is granted only after the testing process,” he said.
The procurement of Adalimumab is part of the state’s effort to maintain stocks of essential biologic medications used for conditions such as rheumatoid arthritis and psoriasis in both adults and children.
Sri Lanka has recently stepped up its scrutiny of medical imports following quality failures in several drug batches last year, which prompted the health ministry to enforce stricter laboratory testing protocols before clinical use. (Colombo/May1/2026)